Risk factor
Very poor trading liquidity
Profitability factor
Very favourable analyst view
About
This company specializes in the development of innovative regenerative bio-orthopedic products. Its current pipeline includes BiG-001 and BiG-006, both of which are osteoinductive bone graft substitutes. Additionally, it is advancing BiG-009, an autologous cartilage repair system. Established in 2016, the firm's operations are based in Taipei, Taiwan.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is overvalued on EV/EBITDA.
Target Price
The average target price of 6733.TWO is 49.0 and suggests 95.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to